Zinc Launches GBP70M Science-for-Impact Fund with UK Bank Backing
TL;DR
Zinc, the London-based pre-seed venture firm founded in 2017 by Paul Kirby and Ella Goldner, has launched its Science-for-Impact Fund at £70 million (€81.5 million), with the British Business Bank committing up to £46 million (€53.6 million) through its Enterprise Capital Funds programme. The fund will back roughly 80 new deep-tech companies translating UK scientific research into commercial ventures across health and environmental challenges, writing first checks of up to £300,000 alongside hands-on venture-building support. It's a notable vote of confidence from the UK's state-backed development bank in a founder-led, venture-building model rather than a traditional pre-seed fund, and it lands squarely inside the government's Industrial Strategy priority sectors of advanced manufacturing, clean energy and life sciences.
Key Takeaways
Nearly two-thirds of the fund is government-backed capital. The British Business Bank's up to £46 million commitment against a £70 million total means state capital is doing the heavy lifting here, which is both a strong validation signal and a reminder that UK deep-tech pre-seed investing still leans heavily on public-sector risk appetite rather than private LP conviction alone. That's not unique to Zinc, it's the pattern across most UK deep-tech specialist funds of this size, but it's worth naming plainly rather than treating a British Business Bank-backed close as equivalent to an independently-raised institutional fund.
This is Zinc's second institutional fund, and the model has been validated once already. Zinc launched its first "for-good" tech fund back in 2017 and has spent the years since building out a venture-studio-style model that pairs capital with founding-team formation, fellow networks and coaching. A £70 million second fund from a firm that started as a relatively unusual venture-building experiment suggests the model has produced enough portfolio traction (SignaCor, Epiome, Speek, Spine and CellMine are among the named companies) to justify a meaningfully larger vehicle and a flagship institutional LP.
The thesis is deliberately narrow: scientist-founders, not just science-adjacent startups. Zinc isn't simply investing in deep tech, it's specifically targeting the translation problem, world-class UK research that never becomes a company because the scientists behind it lack commercial or founding experience. The firm's check is paired with venture-building support explicitly designed to solve that gap, which differentiates it from generalist deep-tech seed funds that expect a formed team and a pitch deck on day one.
Health and environment as a combined mandate is unusual and intentional. Most specialist deep-tech funds pick one vertical. Zinc is explicitly running health and environmental impact as a single fund thesis, betting that the underlying founder profile, pattern (scientific breakthrough in search of a commercial vehicle) and venture-building playbook are similar enough across both verticals to justify one team and one fund rather than two.
Fund Overview
Fund Name: Zinc Science-for-Impact Fund
Fund Size: £70 million (€81.5 million) total, with the British Business Bank committing up to £46 million (€53.6 million)
Stage: Pre-seed
Check Size: Up to £300,000 as first-cheque capital, paired with venture-building support
Geography: United Kingdom
Focus: Science-driven, founder-led ventures addressing health and environmental challenges, aligned with UK Industrial Strategy priorities in advanced manufacturing, clean energy and life sciences, plus AI, engineering and biology
Key LPs: British Business Bank (up to £46 million, via its Enterprise Capital Funds programme)
Why This Fund Matters
The UK has a well-documented deep-tech translation gap: world-leading university research that consistently fails to convert into venture-scale companies at the rate you'd expect given the country's research output. Government strategy documents have flagged this for years, and the British Business Bank's Enterprise Capital Funds programme exists specifically to de-risk private capital into exactly this kind of early-stage, high-technical-risk investing where purely private LPs are historically reluctant to commit at scale. A £46 million commitment to a single manager is a meaningful vote that Zinc's venture-building model, not just its investment thesis, is the right mechanism for closing that gap.
What makes Zinc's approach distinct from a typical deep-tech seed fund is the emphasis on founder formation rather than founder selection. Many pre-seed deep-tech investors are effectively picking from a pool of already-formed teams with a demo and a deck. Zinc's model, drawing on its "Fellows" network and structured coaching, is closer to a venture studio: identifying scientists and researchers with commercially viable IP and helping build the founding team and company around them from a much earlier point. That's a more capital- and time-intensive model per company, which is part of why check sizes are capped relatively low at £300,000 and why the value-add narrative matters as much as the capital.
The dual health-and-environment mandate also reflects where a meaningful share of UK deep-tech capital and government industrial strategy attention has concentrated. Life sciences and clean energy are two of the government's explicitly named Industrial Strategy priority sectors, and a fund that can credibly operate across both, backed by a state development bank with a mandate to support exactly those sectors, is well-positioned to capture policy tailwinds, sector-specific grant and non-dilutive funding co-investment opportunities, and follow-on interest from both healthcare-focused and climate-focused generalist funds as portfolio companies mature.
The honest tension worth flagging is scale versus ambition. Eighty portfolio companies from a £70 million fund, after accounting for the venture-building overhead this model requires, implies genuinely small average check sizes and a portfolio construction that depends heavily on a small number of breakout winners to return the fund, the standard seed-stage math, but more acute here given how capital-intensive and slow-moving deep-tech commercialisation typically is relative to software. Zinc's own framing, up to £300,000 as a first cheque rather than a company's full seed round, suggests the firm is explicitly underwriting a syndicate model where its capital catalyses larger rounds from co-investors rather than fully funding companies itself.
The Team
Zinc was co-founded in 2017 by Paul Kirby and Ella Goldner, who both currently serve as Managing Partners and are the firm's day-to-day leadership. Saul Klein, a well-known figure in UK venture as a co-founder of LocalGlobe and Seedcamp, is a co-founder and board member of Zinc but is not a Managing Partner in the current structure, a distinction worth making given his higher public profile relative to the operating partners actually running the fund.
Beneath the Managing Partners, Zinc runs a sector-split investment team: Natalie Pankova serves as Partner, Health & Life Sciences, and Martin Sellers is Head Venture Partner, Environment, reflecting the fund's dual-vertical structure. Lily Mcfarlane holds the Partner, Product role, and the venture partner bench includes David Herbada and Mark Bailey. Operational leadership includes Claire Hankey as Finance Director, Eleanor Ford as Chief People Officer and Kate Hyslop as Head of Marketing, while Emilie Syed serves as Investment Principal. A related but organisationally distinct entity, Zinc Innovation Partners, is led by co-founder and CEO Polly Mackenzie and co-founder and Chief Scientist Rachel Carey, and appears to operate the innovation and venture-building programming that feeds into the fund's founder-formation model.
Early Portfolio
Named portfolio companies from Zinc's science-for-impact thesis include SignaCor, working on heart disease therapeutics; Epiome, an AI-driven biomarker platform; Speek, a digital mental health platform; Spine, which builds AI for battery management; and CellMine, focused on lithium-ion battery recycling. The spread across therapeutics, AI-enabled diagnostics, mental health and battery/materials technology illustrates the breadth the fund is underwriting within its stated health-and-environment mandate, and is consistent with a venture-building model that starts from scientific IP and technical founders rather than a narrower vertical thesis.
What This Means for Founders
If you're a UK-based scientist or researcher with commercially promising IP but little or no existing company or founding team, Zinc's model is built specifically for you in a way most pre-seed funds are not. The firm's pitch isn't just capital, it's structured help forming a founding team, accessing a Fellows network of advisors and funders, and coaching through the earliest, most ambiguous stage of turning research into a company, which is exactly the stage most traditional venture investors are unequipped or unwilling to support.
Founders should expect the initial check, up to £300,000, to function as a foundation-laying investment rather than a full pre-seed round, meaning Zinc's own materials and the broader Enterprise Capital Funds structure point toward this being the first close in a syndicate rather than the whole answer to early capital needs. Given the fund's explicit alignment with UK Industrial Strategy sectors, founders working in advanced manufacturing, clean energy or life sciences, in particular anything touching decarbonisation, sustainable materials, energy storage or health diagnostics, are likely to find the clearest thesis fit and the strongest access to Zinc's sector-specific venture partners.
Fund Momentum Take
This is a well-timed and well-structured fund for what the UK deep-tech ecosystem actually needs right now, which is patient, hands-on capital willing to work with scientists before they look like conventional venture-backable founders. The British Business Bank's outsized commitment relative to total fund size is the real story here: it's a meaningful bet by the state that Zinc's venture-building model, not just its stock-picking, is worth subsidising at scale, and it will likely make it easier for other UK deep-tech funds pursuing a similar founder-formation approach to attract Enterprise Capital Funds-style institutional backing going forward.
Our skepticism is narrow and structural rather than thesis-level. Eighty portfolio companies from £70 million, net of the venture-building overhead the model requires, means individual company check sizes will be genuinely small, and the fund's economics will depend on a handful of the therapeutics or deep-tech bets scaling into large enough outcomes to carry a long tail of modest ones, a return profile that's harder to underwrite in capital-intensive health and hard-tech sectors than in software. We'd also watch whether the health/environment dual mandate stays coherent as the fund scales or whether it eventually splits into two more specialised vehicles, the way many multi-vertical seed funds do once they have enough track record to raise sector-specific successor funds. Net: a fund worth watching closely, and one of the more interesting validations yet of the venture-studio-adjacent model for deep-tech pre-seed investing in the UK.
Frequently Asked Questions
How big is Zinc's Science-for-Impact Fund?
The fund totals £70 million (€81.5 million), with the British Business Bank committing up to £46 million (€53.6 million) through its Enterprise Capital Funds programme.
What stage and sectors does the fund target?
Pre-seed investments in science-driven, founder-led ventures across health and environmental challenges, aligned with UK Industrial Strategy priority sectors including advanced manufacturing, clean energy and life sciences.
What is Zinc's check size?
Up to £300,000 as an initial cheque, combined with structured venture-building support to help scientist-founders form companies and founding teams.
Who leads Zinc?
Paul Kirby and Ella Goldner are co-founders and Managing Partners. Saul Klein, also a co-founder, serves as a board member rather than a Managing Partner in the firm's current structure.
Is this Zinc's first fund?
No. Zinc was founded in 2017 and has raised earlier capital under a "for-good" tech investing model; the Science-for-Impact Fund is described as the firm's second institutional fund and a significant step up in scale and formalised state-backed LP support.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.